Pain during or after injection Some discomfort is normal, but injection should not be significantly painful
Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis
Nausea, diarrhea, and vomiting were all significantly higher in the direct-start group
Pain outcomes (WOMAC pain score): Additional findings: Systolic blood pressure reduced by 14 mmHg at 12 mg Improved non-HDL cholesterol, triglycerides, and hsCRP (a marker of inflammation) New safety signal -- dysesthesia: Dysesthesia (abnormal sensations such as burning, tingling, or numbness) emerged as a new adverse event in this trial: 8.8% at 9 mg 20.9% at 12 mg 0.7% at placebo TRIUMPH-5 -- Head-to-Head vs Tirzepatide TRIUMPH-5 is a Phase 3 head-to-head efficacy trial comparing retatrutide to tirzepatide in adults with obesity
GLP-1R causes a reduction in hepatic steatosis and inflammation and increases fat metabolism mediated by increasing hepatic insulin sensitivity [52,53,54]
One thing to remember about ALL MLM products: if something spectacularly innovative and life-changing existed, the FDA would be selling it, not an MLM
